Literature DB >> 26739620

Prognostic factors after pancreatoduodenectomy with en bloc portal venous resection for pancreatic cancer.

Hryhoriy Lapshyn1,2, Peter Bronsert3,4, Louisa Bolm2, Martin Werner3,4,5, Ulrich T Hopt6,7, Frank Makowiec1,4, Uwe A Wittel1,4, Tobias Keck2, Ulrich F Wellner2, Dirk Bausch2.   

Abstract

PURPOSE: Pancreatoduodenectomy (PD) with superior mesenteric/portal venous resection (PVR) for pancreatic ductal adenocarcinoma (PDAC) is performed routinely in case of tumor adhesion to the superior mesenteric or portal vein. True histopathological portal vein invasion (PVI) is found in a subgroup of patients. Even though this procedure has become routine in most centers for pancreatic surgery, data on prognostic factors in this situation is limited. The aim of this study was to identify prognostic factors after PD with PVR for PDAC.
METHODS: Retrospective analysis was performed on the basis of a prospectively maintained database, and paraffin-embedded formalin-fixed tissue slides stained for hematoxylin-eosin were re-evaluated by two independent pathologists. Statistical analysis was conducted using MedCalc software.
RESULTS: From 2001 to 2012, 86 cases of PD with PVR for PDAC with long-term follow-up and sufficient tissue for re-assessment were identified. Histopathological re-review disclosed PVI in 39 resection specimens and adhesion without infiltration in 47. Overall median survival in all patients was 22 months. Patients with PVI versus no PVI showed comparable baseline demographic and standard histopathological parameters; however, PVI was associated with microscopic hemangiosis (p = 0.001) and positive margin status (p = 0.001). Median survival in patients with PVI was 14 months versus 25 months in patients without PVI (p = 0.042). Only lymph node ratio and PVI were independent predictors of survival after resection.
CONCLUSION: The only independent factors influencing overall survival after PD with PVR for PDAC were lymph node ratio and PVI. PVI might indicate aggressive tumor biology, but the available data remains controversial.

Entities:  

Keywords:  Median survival; Pancreatic ductal adenocarcinoma; Pancreatoduodenectomy; Portal venous resection; Portal venous tumor infiltration

Mesh:

Year:  2016        PMID: 26739620     DOI: 10.1007/s00423-015-1363-2

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  24 in total

Review 1.  Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review.

Authors:  Terence C Chua; Akshat Saxena
Journal:  J Gastrointest Surg       Date:  2010-04-09       Impact factor: 3.452

2.  Portal or superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head carcinoma.

Authors:  Y Murakami; S Satoi; F Motoi; M Sho; M Kawai; I Matsumoto; G Honda
Journal:  Br J Surg       Date:  2015-04-15       Impact factor: 6.939

Review 3.  Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.

Authors:  Matthew H G Katz; Robert Marsh; Joseph M Herman; Qian Shi; Eric Collison; Alan P Venook; Hedy L Kindler; Steven R Alberts; Philip Philip; Andrew M Lowy; Peter W T Pisters; Mitchell C Posner; Jordan D Berlin; Syed A Ahmad
Journal:  Ann Surg Oncol       Date:  2013-02-23       Impact factor: 5.344

Review 4.  Resection margins in pancreatic cancer.

Authors:  Caroline S Verbeke
Journal:  Surg Clin North Am       Date:  2013-03-29       Impact factor: 2.741

5.  Vein involvement during pancreaticoduodenectomy: is there a need for redefinition of "borderline resectable disease"?

Authors:  Kaitlyn J Kelly; Emily Winslow; David Kooby; Neha L Lad; Alexander A Parikh; Charles R Scoggins; Syed Ahmad; Robert C Martin; Shishir K Maithel; H J Kim; Nipun B Merchant; Clifford S Cho; Sharon M Weber
Journal:  J Gastrointest Surg       Date:  2013-04-26       Impact factor: 3.452

6.  The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database.

Authors:  Anthony W Castleberry; Rebekah R White; Sebastian G De La Fuente; Bryan M Clary; Dan G Blazer; Richard L McCann; Theodore N Pappas; Douglas S Tyler; John E Scarborough
Journal:  Ann Surg Oncol       Date:  2012-08-30       Impact factor: 5.344

7.  Correlation between radiographic classification and pathological grade of portal vein wall invasion in pancreatic head cancer.

Authors:  Akimasa Nakao; Akiyuki Kanzaki; Tsutomu Fujii; Yasuhiro Kodera; Suguru Yamada; Hiroyuki Sugimoto; Shuji Nomoto; Shigeo Nakamura; Satoshi Morita; Shin Takeda
Journal:  Ann Surg       Date:  2012-01       Impact factor: 12.969

8.  Clinical implications of combined portal vein resection as a palliative procedure in patients undergoing pancreaticoduodenectomy for pancreatic head carcinoma.

Authors:  Kazuaki Shimada; Tsuyoshi Sano; Yoshihiro Sakamoto; Tomoo Kosuge
Journal:  Ann Surg Oncol       Date:  2006-12       Impact factor: 5.344

9.  Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma.

Authors:  F Wang; A J Gill; M Neale; V Puttaswamy; S Gananadha; N Pavlakis; S Clarke; T J Hugh; J S Samra
Journal:  Ann Surg Oncol       Date:  2014-02-21       Impact factor: 5.344

10.  Pancreaticoduodenectomy combined with vascular resection and reconstruction for patients with locally advanced pancreatic cancer: a multicenter, retrospective analysis.

Authors:  Yi Gong; Leida Zhang; Tieying He; Jun Ding; Hongyu Zhang; Geng Chen; Dong Zhang; Zheng Wu; Qilong Chen; Haining Fan; Qi Wang; Ping Bie; Huaizhi Wang
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

View more
  5 in total

1.  Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer.

Authors:  Kim C Honselmann; Ilaria Pergolini; Carlos Fernandez-Del Castillo; Vikram Deshpande; David Ting; Martin S Taylor; Louisa Bolm; Motaz Qadan; Ulrich Wellner; Marta Sandini; Dirk Bausch; Andrew L Warshaw; Keith D Lillemoe; Tobias Keck; Cristina R Ferrone
Journal:  Ann Surg       Date:  2019-01-18       Impact factor: 12.969

Review 2.  Histopathologic tumor invasion of superior mesenteric vein/ portal vein is a poor prognostic indicator in patients with pancreatic ductal adenocarcinoma: results from a systematic review and meta-analysis.

Authors:  Ailin Song; Farong Liu; Lupeng Wu; Xiaoying Si; Yanming Zhou
Journal:  Oncotarget       Date:  2017-05-16

3.  Predictive risk factors for early recurrence in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection after preoperative chemoradiotherapy.

Authors:  Yasuhiro Murata; Toru Ogura; Aoi Hayasaki; Kazuyuki Gyoten; Takahiro Ito; Yusuke Iizawa; Takehiro Fujii; Akihiro Tanemura; Naohisa Kuriyama; Masashi Kishiwada; Hiroyuki Sakurai; Shugo Mizuno
Journal:  PLoS One       Date:  2022-04-04       Impact factor: 3.240

4.  Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer.

Authors:  Kim C Honselmann; Ilaria Pergolini; Carlos Fernandez-Del Castillo; Vikram Deshpande; David Ting; Martin S Taylor; Louisa Bolm; Motaz Qadan; Ulrich Wellner; Marta Sandini; Dirk Bausch; Andrew L Warshaw; Keith D Lillemoe; Tobias Keck; Cristina R Ferrone
Journal:  Ann Surg       Date:  2020-08       Impact factor: 13.787

5.  Facile assembly of upconversion nanoparticle-based micelles for active targeted dual-mode imaging in pancreatic cancer.

Authors:  Yong Han; Yanli An; Gang Jia; Xihui Wang; Chen He; Yinan Ding; Qiusha Tang
Journal:  J Nanobiotechnology       Date:  2018-01-29       Impact factor: 10.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.